Apyx Medical Inc
Apyx Medical Corporation, an energy technology company, designs, develops, manufactures, and sells electrosurgical equipment and medical devices in the United States and internationally. The company operates through two segments: Advanced Energy and Original Equipment Manufacturing (OEM). It offers helium plasma generator for the delivery of RF energy and helium plasma to cut, coagulate, and abla… Read more
Apyx Medical Inc (APYX) - Net Assets
Latest net assets as of September 2025: $6.08 Million USD
Based on the latest financial reports, Apyx Medical Inc (APYX) has net assets worth $6.08 Million USD as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($57.37 Million) and total liabilities ($51.28 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $6.08 Million |
| % of Total Assets | 10.6% |
| Annual Growth Rate | 13.02% |
| 5-Year Change | -77.55% |
| 10-Year Change | -38.75% |
| Growth Volatility | 125.88 |
Apyx Medical Inc - Net Assets Trend (1995–2024)
This chart illustrates how Apyx Medical Inc's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Apyx Medical Inc (1995–2024)
The table below shows the annual net assets of Apyx Medical Inc from 1995 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | $14.34 Million | -46.75% |
| 2023-12-31 | $26.92 Million | -28.76% |
| 2022-12-31 | $37.79 Million | -30.02% |
| 2021-12-31 | $54.01 Million | -15.42% |
| 2020-12-31 | $63.86 Million | -10.38% |
| 2019-12-31 | $71.26 Million | -18.81% |
| 2018-12-31 | $87.77 Million | +298.37% |
| 2017-12-31 | $22.03 Million | -15.98% |
| 2016-12-31 | $26.22 Million | +12.04% |
| 2015-12-31 | $23.40 Million | +398.59% |
| 2014-12-31 | $4.69 Million | -77.99% |
| 2013-12-31 | $21.33 Million | -6.84% |
| 2012-12-31 | $22.89 Million | +3.52% |
| 2011-12-31 | $22.12 Million | +1.62% |
| 2010-12-31 | $21.77 Million | +2.89% |
| 2009-12-31 | $21.15 Million | +12.59% |
| 2008-12-31 | $18.79 Million | +11.89% |
| 2007-12-31 | $16.79 Million | +18.42% |
| 2006-12-31 | $14.18 Million | +42.64% |
| 2005-12-31 | $9.94 Million | +7.40% |
| 2004-12-31 | $9.26 Million | +24.25% |
| 2003-12-31 | $7.45 Million | +14.77% |
| 2002-12-31 | $6.49 Million | -7.27% |
| 2001-12-31 | $7.00 Million | +9.49% |
| 2000-12-31 | $6.39 Million | +6.32% |
| 1999-12-31 | $6.01 Million | -35.25% |
| 1998-12-31 | $9.29 Million | +317.51% |
| 1997-12-31 | $2.22 Million | +10.12% |
| 1996-12-31 | $2.02 Million | +389.98% |
| 1995-12-31 | $412.30K | -- |
Equity Component Analysis
This analysis shows how different components contribute to Apyx Medical Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 6672810000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $38.00K | 0.27% |
| Other Components | $92.08 Million | 648.02% |
| Total Equity | $14.21 Million | 100.00% |
Apyx Medical Inc Competitors by Market Cap
The table below lists competitors of Apyx Medical Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Andrew Peller Limited
PINK:ADWPF
|
$98.78 Million |
|
Silver Tiger Metals Inc
OTCQX:SLVTF
|
$98.79 Million |
|
Sam Holdings Corp
VN:SAM
|
$98.81 Million |
|
Guandian Defense Technology Co. Ltd. A
SHG:688287
|
$98.84 Million |
|
ALi Corp
TW:3041
|
$98.65 Million |
|
Teqnion AB
ST:TEQ
|
$98.64 Million |
|
Thryv Holdings Inc
NASDAQ:THRY
|
$98.64 Million |
|
Mosel Vitelic Inc
TW:2342
|
$98.63 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Apyx Medical Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 26,701,000 to 14,210,000, a change of -12,491,000 (-46.8%).
- Net loss of 23,463,000 reduced equity.
- New share issuances of 7,000,000 increased equity.
- Other factors increased equity by 3,972,000.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-23.46 Million | -165.12% |
| Share Issuances | $7.00 Million | +49.26% |
| Other Changes | $3.97 Million | +27.95% |
| Total Change | $- | -46.78% |
Book Value vs Market Value Analysis
This analysis compares Apyx Medical Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 9.35x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has decreased from 39.50x to 9.35x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 1995-12-31 | $0.09 | $3.74 | x |
| 1996-12-31 | $0.26 | $3.74 | x |
| 1997-12-31 | $0.26 | $3.74 | x |
| 1998-12-31 | $0.67 | $3.74 | x |
| 1999-12-31 | $0.43 | $3.74 | x |
| 2000-12-31 | $0.40 | $3.74 | x |
| 2001-12-31 | $0.47 | $3.74 | x |
| 2002-12-31 | $0.45 | $3.74 | x |
| 2003-12-31 | $0.55 | $3.74 | x |
| 2004-12-31 | $0.55 | $3.74 | x |
| 2005-12-31 | $0.62 | $3.74 | x |
| 2006-12-31 | $0.83 | $3.74 | x |
| 2007-12-31 | $0.95 | $3.74 | x |
| 2008-12-31 | $1.10 | $3.74 | x |
| 2009-12-31 | $1.19 | $3.74 | x |
| 2010-12-31 | $1.25 | $3.74 | x |
| 2011-12-31 | $1.25 | $3.74 | x |
| 2012-12-31 | $1.29 | $3.74 | x |
| 2013-12-31 | $1.21 | $3.74 | x |
| 2014-12-31 | $0.26 | $3.74 | x |
| 2015-12-31 | $0.84 | $3.74 | x |
| 2016-12-31 | $0.96 | $3.74 | x |
| 2017-12-31 | $0.70 | $3.74 | x |
| 2018-12-31 | $2.55 | $3.74 | x |
| 2019-12-31 | $2.09 | $3.74 | x |
| 2020-12-31 | $1.86 | $3.74 | x |
| 2021-12-31 | $1.56 | $3.74 | x |
| 2022-12-31 | $1.09 | $3.74 | x |
| 2023-12-31 | $0.77 | $3.74 | x |
| 2024-12-31 | $0.40 | $3.74 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Apyx Medical Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -165.12%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -48.78%
- • Asset Turnover: 0.74x
- • Equity Multiplier: 4.56x
- Recent ROE (-165.12%) is below the historical average (-24.17%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 1995 | -37.38% | -2.79% | 1.53x | 8.73x | $-195.33K |
| 1996 | 20.16% | 5.44% | 1.92x | 1.93x | $205.28K |
| 1997 | 4.46% | 1.35% | 1.92x | 1.72x | $-123.28K |
| 1998 | -10.75% | -11.82% | 0.79x | 1.15x | $-1.93 Million |
| 1999 | -36.31% | -22.75% | 1.31x | 1.22x | $-2.79 Million |
| 2000 | 7.83% | 5.04% | 1.26x | 1.24x | $-138.74K |
| 2001 | 11.20% | 6.83% | 1.34x | 1.23x | $84.26K |
| 2002 | -7.93% | -4.14% | 1.46x | 1.31x | $-1.16 Million |
| 2003 | 9.15% | 4.12% | 1.79x | 1.24x | $-63.67K |
| 2004 | 16.33% | 7.38% | 1.86x | 1.19x | $586.34K |
| 2005 | 4.14% | 2.01% | 1.72x | 1.20x | $-573.95K |
| 2006 | 19.08% | 10.06% | 1.60x | 1.19x | $1.28 Million |
| 2007 | 14.30% | 8.34% | 1.53x | 1.12x | $721.40K |
| 2008 | 9.75% | 6.52% | 1.09x | 1.37x | $-47.00K |
| 2009 | 2.82% | 2.21% | 0.98x | 1.30x | $-1.52 Million |
| 2010 | -7.05% | -6.34% | 0.87x | 1.28x | $-3.71 Million |
| 2011 | 0.49% | 0.43% | 0.90x | 1.28x | $-2.10 Million |
| 2012 | 2.69% | 2.23% | 0.98x | 1.23x | $-1.67 Million |
| 2013 | -20.34% | -18.34% | 0.71x | 1.56x | $-6.47 Million |
| 2014 | -368.17% | -62.43% | 1.11x | 5.29x | $-17.75 Million |
| 2015 | -22.94% | -18.19% | 0.94x | 1.34x | $-7.71 Million |
| 2016 | -15.06% | -10.78% | 1.04x | 1.34x | $-6.57 Million |
| 2017 | -22.98% | -13.02% | 1.25x | 1.41x | $-7.27 Million |
| 2018 | 72.93% | 383.61% | 0.17x | 1.09x | $55.23 Million |
| 2019 | -27.65% | -69.79% | 0.33x | 1.19x | $-26.83 Million |
| 2020 | -18.67% | -42.93% | 0.37x | 1.16x | $-18.27 Million |
| 2021 | -28.25% | -31.27% | 0.71x | 1.28x | $-20.54 Million |
| 2022 | -61.69% | -52.09% | 0.86x | 1.38x | $-26.94 Million |
| 2023 | -70.08% | -35.75% | 0.66x | 2.97x | $-21.38 Million |
| 2024 | -165.12% | -48.78% | 0.74x | 4.56x | $-24.88 Million |
Industry Comparison
This section compares Apyx Medical Inc's net assets metrics with peer companies in the Medical Devices industry.
Industry Context
- Industry: Medical Devices
- Average net assets among peers: $694,749,556
- Average return on equity (ROE) among peers: -25.46%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Apyx Medical Inc (APYX) | $6.08 Million | -37.38% | 8.44x | $98.75 Million |
| Advanced Biomedical Technologies Inc (ABMT) | $-4.46 Million | 0.00% | 0.00x | $14.18K |
| Abbott Laboratories (ABT) | $4.82 Billion | 39.04% | 1.31x | $191.37 Billion |
| Acarix AB (publ) (ACIXF) | $1.93 Million | -127.02% | 0.21x | $26.42 Million |
| Adagio Medical Holdings, Inc Common Stock (ADGM) | $-72.62 Million | 0.00% | 0.00x | $4.05 Million |
| Adm Tronics Unltd (ADMT) | $-12.69K | 0.00% | 0.00x | $3.17 Million |
| Aethlon Medical Inc (AEMD) | $-3.07 Million | 0.00% | 0.00x | $2.79 Million |
| Acutus Medical Inc (AFIB) | $126.58 Million | -80.56% | 0.52x | $732.88K |
| Adapthealth Corp (AHCO) | $2.07 Billion | 7.56% | 1.54x | $914.25 Million |
| Allied Healthcare Products Inc. (AHPIQ) | $8.88 Million | -33.95% | 1.22x | $726.24 |
| 20/20 Biolabs, Inc. Common Stock (AIDX) | $3.39 Million | -59.65% | 0.38x | $9.18 Million |